Moreover, in anti-MAG patients, hematological follow-up is required due to the progression risk of M-component to hematological malignancies, such as multiple myeloma, Waldenstrom macroglobulinemia, amyloid light-chain (AL) amyloidosis, with an approximate risk of 1% per year [53]. This evidence concerns the gene MAG and Waldenstrom macroglobulinemia.